DexTech Says OsteoDex Meets Study Goals in Multiple Myeloma
DexTech Medical says OsteoDex met its study goals in multiple myeloma. The supplied report says the study took place in October.
Related stories
Microsoft Expects to Raise About $25 Billion in U.S. Bond Sale
Microsoft expects to raise about $25 billion through a U.S. bond sale, according to a source.
M impact | EQUITY | Oct 29, 2026, 04:20 PM UTC
NYSE Halt Adds Information on LST at $5.80
L impact | EQUITY | Oct 29, 2026, 04:17 PM UTC
Viridian Metals Plans Private Placement of Up to CA$5 Million
Viridian Metals plans to raise up to CA$5 million through a private placement of units.
L impact | EQUITY | Oct 29, 2026, 04:16 PM UTC
Waterland to Acquire 50% Stake in Milieu Service Groep
Waterland Private Equity agreed to acquire a 50% stake in Milieu Service Groep.
M impact | EQUITY | Oct 29, 2026, 04:14 PM UTC
Shrieve Chemical Acquires Research Solutions Group to Expand Southeast Reach
Shrieve Chemical Company acquired Research Solutions Group to expand its reach in the US Southeast.
M impact | EQUITY | Oct 29, 2026, 04:13 PM UTC
Tide Rock Acquires Electro-Spec
Tide Rock LLC acquired Electro-Spec to establish a surface-finishing platform.
M impact | EQUITY | Oct 29, 2026, 04:13 PM UTC